1887
Volume 2009, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Respiratory syncytial virus (RSV) is one of the most common causes of infection of the lower respiratory tract in infants and young children. In the United States RSV is responsible for 90,000 hospitalizations and 4,500 deaths each year 1, 1. Fleming, Pannell, and Cross3 reported that the average death rate from RSV is 6.7 per 100,000 population. Infants with congenital cardiac defects are at greater risk because changes associated with congestive heart failure and cardiac defects limit the ability to compensate during viral bronchiolitis, which in turn increases morbidity and mortality associated with this viral illness4,5. The infection can cause serious illness, prolonged hospitalization, and increased post-operative complications after surgical repair for children with congenital heart malformations6’ 7 ’8. There may also be long term sequelae, proven by a number of studies linking the infection with increased risk of subsequent development of reactive airway disease9,10, 11 compromising the ability of children with congenital heart disease to return to baseline.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2009.1.16
2009-05-01
2019-12-09
Loading full text...

Full text loading...

References

  1. Ogra PL. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus. Pediatr Infect Dis J. 2000; 19::774779.
    [Google Scholar]
  2. Prober C, Sullender W. Advance in prevention of respiratory syncytial virus infections. J pediatr. 1999; 135::546558.
    [Google Scholar]
  3. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health. 2005; 59::586590.
    [Google Scholar]
  4. Sandritter T. Palivizumab for Respiratory Syncytial Virua Prophylaxis. Journal Of Pediatric Health Care. 1999; 13::191195.
    [Google Scholar]
  5. Bonnet D, Schmaltz AA, Feltes TF. Infection by the respiratory syncytial virus in infants and young children at high risk. Cardiology of the Young. 2005; 15::256265.
    [Google Scholar]
  6. Feltes TF, Groothuis JR. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations. Cardiology of the Young. 2005; 15::266273.
    [Google Scholar]
  7. Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (Palivizumab). Pediatrics International. 2002; 44::235241.
    [Google Scholar]
  8. MacDonal NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982; 307::397400.
    [Google Scholar]
  9. Altman CA, Englund JA, Demmler G, Drescher KL, Alexander MA, Watrin C, Feltes TF. Respiratory Syncytial Virus in Patient with Congenital Heart Disease: A Contemporary look at epidemiology and success of preoperative screening. Pediatric cardiology. 2000; 21::433438.
    [Google Scholar]
  10. Klongphatthanayothen JA, Wong PC, Samara Y, Newth CT, Wells WT, Starnes VA, Chang AC. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med. 1999; 27:9:1974198L.
    [Google Scholar]
  11. Tulloh , Robert MR, Feltes TF. The European Forum For Clinical Management: prophylaxis against the respiratory syncytial virus in infant and young children with congenital heart disease. Cardiology in the young. 2005; 15:3:274278.
    [Google Scholar]
  12. Meissner CH, Anderson JL, Pickering KL, Annual variation in respiratory syncytial virus season and decision regarding immunoprophylaxis with Palivizumab Pediatrics. 2004; 114:4:10821084.
    [Google Scholar]
  13. Welliver RC. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin Perinatol. 1998; 22::8795.
    [Google Scholar]
  14. Welliver RC, Wong DT, Sun M, Middleton E Jr, Vaughan RS, Ogra PL. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med. 1981; 305:841846.
    [Google Scholar]
  15. Sigurs N, Bjarnason R, Sigurgergsson F, Kjellman B, &Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995; 95::500505.
    [Google Scholar]
  16. Sigurs N, Gustafsson P, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Bengt Kjellman. Severe Respiratory syncytial virus bronchiolitis in infancy and Asthma and allergy at age 13. Am J Respir Crit Care Med. 2005; 171::137141.
    [Google Scholar]
  17. Feltes T, Cabalka A, Meissner C, Piazza F, Carlin D, Top F, Connor E, Sondheimer H, cardiac Synagis Study Group . Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of pediatrics. 2003; 143::532540.
    [Google Scholar]
  18. Stevens T, Hall C. Controversies in Palivizumab use. The pediatric infectious disease journal. 2004; 23::10511052.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2009.1.16
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error